Promising results for SPC-14 in small animal study
- Silo Pharma’s Alzheimer’s disease therapeutic SPC-14 shows positive efficacy in small animals
- Study conducted in collaboration with Columbia University
- SPC-14 effective against luteinizing hormone stress
- Attenuates learned helplessness, perseverative behavior, and hyponeophagia
- Mice treated twice daily with SPC-14 therapeutic
- Discovery of a potential therapeutic for Alzheimer’s disease
Silo Pharma has announced positive data from a study conducted in collaboration with Columbia University, showcasing the efficacy of their Alzheimer’s disease therapeutic, SPC-14. The study demonstrated that SPC-14 was effective in attenuating learned helplessness, perseverative behavior, and hyponeophagia, which are associated with Alzheimer’s disease. The mice in the study were treated twice daily with the SPC-14 therapeutic. Silo Pharma’s CEO, Eric Weisblum, believes that these findings, combined with previous studies conducted in female rodents, provide credibility to their discovery of a potential therapeutic for Alzheimer’s disease. This development brings hope for patients and families affected by this debilitating condition.
Public Companies: Silo Pharma (N/A)
Private Companies:
Key People: Eric Weisblum (Chief Executive of Silo Pharma)
Factuality Level: 7
Justification: The article provides information about a study conducted by Silo Pharma in collaboration with Columbia University, which showed positive efficacy of their Alzheimer’s disease therapeutic SPC-14 in small animals. The article includes a quote from the CEO of Silo Pharma, expressing belief in the potential of the therapeutic. However, the article lacks specific details about the study, such as sample size, methodology, and statistical significance. Without these details, it is difficult to fully assess the validity and reliability of the study’s findings. Therefore, the factuality level is rated at 7.
Noise Level: 7
Justification: The article provides some information about Silo Pharma’s Alzheimer’s disease therapeutic SPC-14 showing positive efficacy in small animals. However, it lacks important details such as the sample size, methodology, and statistical significance of the results. The article also does not provide any context or comparison to existing treatments or research in the field. Overall, the article is quite brief and lacks in-depth analysis or evidence to support its claims.
Financial Relevance: No
Financial Markets Impacted: No
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article does not pertain to financial topics and does not describe any extreme events. It provides information about Silo Pharma’s Alzheimer’s disease therapeutic showing positive efficacy in small animals.
www.marketwatch.com 
